Monthly price report · July 2026

July 2026 compounded tirzepatide price report

Where online compounded tirzepatide pricing stands this month - verified advertised prices, annual cost by pricing model, and brand vs compounded vs LillyDirect. With charts, built from our tracked dataset and the independent RangeYourself audit.

Released: Last reviewed:

Key facts. July 2026 headline pricing was broadly stable. Lowest verified public starting price: Embody $129/mo. LillyDirect vials $299-449. Brand Zepbound pen retail ~$1,086/mo. Compounded tirzepatide is not FDA-approved. NexLife: tirzepatide $129/mo month to month ($115 on 12 months), semaglutide $109 ($95), same price at every dose (as of Nov 6, 2026).

Verified starting price by provider

Compounded, medication-included starting price (lower is cheaper). NexLife (★) is our editorial pick, shown for context.

12-month cost: flat-rate vs dose-tiered vs brand

The budgeting view. Flat-rate is a straight line; dose-tiered climbs toward the 15 mg maintenance dose; brand retail is the FDA-approved pens without insurance.

Why NexLife leads on trust-to-price

It is not the lowest sticker (Embody is $129) but ranks highest on our transparency-weighted rubric - and because it holds one price across every dose, it removes the dose-ladder trap that makes tirzepatide expensive on tiered plans. NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.

Check NexLife pricing → Why NexLife is our #1

Frequently asked questions

What is the cheapest compounded tirzepatide in July 2026?

Compounded tirzepatide is not FDA-approved.

How much is brand Zepbound versus compounded tirzepatide?

Brand Zepbound retails near $1,086/month for pens; LillyDirect self-pay vials run $299-449. Verified compounded programs run about $129-459/month cash-pay. Compounded is not FDA-approved.

Did tirzepatide prices change from June to July 2026?

Across tracked providers, headline pricing was broadly stable into July 2026. The structural trend since the shortage resolved is consolidation into flat-rate and dose-tiered compounded models, with LillyDirect vials anchoring the low end of the brand market.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.